Stocktoria
EDAP TMS SA FOCL
EDAP TMS SA (FOCL) earns a Piotroski F-score of 3/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $70.5M at a -41.5% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -3.11 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.253 |
| Retained earnings / assets | -1.628 |
| EBIT / assets | -0.313 |
| Equity / liabilities | 0.326 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| FOCL | EDAP TMS SA | 3/9 | -5.4 | — | +1.6% |
| ELMD | Electromed, Inc. | 6/9 | 10.99 | 46.4 | +17% |
| IRIX | IRIDEX CORP | 4/9 | -8.01 | — | +8.2% |
| CBLL | Ceribell, Inc. | 3/9 | 3.97 | — | +36.1% |
| VASO | VASO Corp | 6/9 | 0.72 | 21.3 | +2.7% |
| BLFS | BIOLIFE SOLUTIONS INC | 6/9 | 10.32 | — | +28.9% |
| STXS | Stereotaxis, Inc. | 4/9 | — | — | +20.3% |
About EDAP TMS SA
EDAP TMS S.A., a medical technology company, engages in the development, manufacturing, marketing, and sale of non-invasive therapeutic ultrasound and energy-based medical devices in Asia, France, the United States, and internationally. The company develops, manufactures, markets, and distributes non-invasive robotic HIFU systems for urology-related and other indications. It also offers Focal One, a HIFU robotic system to treat patients diagnosed with prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services. In addition, the company manufactures and markets lithotripter for the treatment of urinary tract stones; and provides disposables, replacement parts, and services for lithotripters; and sells spare parts and disposables, such as electrodes. Further, it markets, distributes, and services lasers, micro-ultrasound systems, and other medical products from third parties, as well as leases devices; sells disposables and spare parts; and offers maintenance services. The company markets and sells its products through its direct marketing, sales channels, and third-party distributors and agents. The company serves academic, public, and private hospitals, as well as clinics. The company has a strategic collaboration with Telix Pharmaceuticals Limited to develop clinical workflows combining PSMA PET imaging and Focal One Robotic HIFU for prostate cancer. EDAP TMS S.A. was incorporated in 1979 and is headquartered in Vaulx-en-Velin, France.
FAQ
Is FOCL financially healthy?
EDAP TMS SA's Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does FOCL pay a dividend?
No, EDAP TMS SA does not currently pay a dividend.
How profitable is FOCL?
In FY2025, EDAP TMS SA had a net margin of -41.5% and a return on equity of -150.7%.
What is the analyst price target for FOCL?
The average Wall-Street price target for EDAP TMS SA is $6.88, about 44.7% above the recent price, from 4 analysts (consensus: buy).
Is FOCL a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on EDAP TMS SA: a Piotroski F-score of 3/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.